EVISA Glossary on | Contact EVISA | Sitemap | Home   
 Advanced search
The establishment of EVISA is funded by the EU through the Fifth Framework Programme (G7RT- CT- 2002- 05112).

Supporters of EVISA includes:

Autism Research

Autism Research is co-owned and supported by The International Society for Autism Research (INSAR), a scientific and professional organization devoted to advancing knowledge about Autism Spectrum Disorder (ASD).


Advanced Technologies & Aerospace Database (ProQuest); BIOSIS Previews (Clarivate Analytics); Current Contents: Social & Behavioral Sciences (Clarivate Analytics); Embase (Elsevier); Health & Medical Collection (ProQuest); Health Research Premium Collection (ProQuest); Hospital Premium Collection (ProQuest); Materials Science & Engineering Database (ProQuest); MEDLINE/PubMed (NLM); ProQuest Central (ProQuest); PsycINFO/Psychological Abstracts (APA); Science Citation Index Expanded (Clarivate Analytics); SciTech Premium Collection (ProQuest); SCOPUS (Elsevier); Social Sciences Citation Index (Clarivate Analytics); Technology Collection (ProQuest);

Source type
First volume
Last volume
Autism Research covers research relevant to ASD and closely related neurodevelopmental disorders. The journal focuses on genetic, neurobiological, immunological, epidemiological and psychological mechanisms and how these influence developmental processes in ASD. The journal encourages the submission of original research papers (Research Articles and Short Reports) that take a developmental approach to the biology and psychology of autism, with a particular emphasis on identifying underlying mechanisms and integrating across different levels of analysis. Contributions are typically empirical, but the journal also publishes theoretical papers if they significantly advance thinking. The journal encourages papers reporting work on animals or cell or other model systems that are directly relevant to a better understanding of ASD. The journal also publishes reports of carefully conducted clinical trials of treatments for the core symptoms or one of the common co-morbid symptoms of ASD. Papers presenting clinical trials will be judged, in part, on whether there is an empirical justification for the reported treatment. Individuals included in research studies can span the full spectrum of ASD, including the broader phenotype, and there are no restrictions on study participants in terms of age or intellectual ability

Imprint     Disclaimer

© 2003 - 2024 by European Virtual Institute for Speciation Analysis ( EVISA )